Last checked at 
(Sharecast News) - Cancer therapy and diagnostics developer Avacta Group has entered into a licence agreement with Point Biopharma, it announced on Thursday, to provide access to its 'preCISION' technology for the development of tumour-activated radiopharmaceuticals.
The AIM-traded company said the radiopharmaceutical market was expected to grow to $15bn by 2025, adding that there was a "substantial opportunity" to grow faster if safety and tolerability of treatments could be improved.
It described Point Biopharma as a clinical-stage pharmaceutical company, focussed on developing radioligands as precision medicines for the treatment of cancer.
Avacta said its proprietary preCISION chemistry could be used to modify a radioligand drug to form a tumour-activated prodrug.
The prodrug form is inactive in circulation until it enters the tumour micro-environment, where it is activated by an enzyme called fibroblast activation protein (FAP) that is present in high abundance in most solid tumours, but not in healthy tissue.
It explained that its preCISION technology thus had the potential to improve tolerability and achieve better clinical outcomes for patients when compared to standard radiopharmaceuticals, by targeting the radioligand treatment more specifically to cancer cells.
The agreement would provide Point with an exclusive licence to the preCISION technology for use in the first radiopharmaceutical prodrug the company intended to develop, and a non-exclusive licence to the platform for the development of a broader pipeline of FAP-activated radiopharmaceuticals.
Under the terms of the deal, Avacta would receive an upfront fee and development milestones for the first radiopharmaceutical prodrug totalling $9.5m (£6.98m).
It would also receive milestone payments for subsequent radiopharmaceutical prodrugs of up to $8m each, a royalty on sales of FAP-activated radiopharmaceuticals by Point, and a percentage of any sublicensing income received by Point.
"The clinical and commercial rationale for our preCISION prodrug platform is to improve the safety and efficacy of many existing drugs, as well as generating a pipeline of new and novel cancer therapies," said chief executive officer Alastair Smith.
"In oncology, we believe that this approach will result in better response rates for monotherapies, and a greater safety margin, to enable their use with a larger patient population and as part of combination therapies."
Smith said the in-house development of AVA6000 pro-doxorubicin, the first of its preCISION chemotherapy prodrugs for which it recently submitted a clinical trial authorisation filing in the UK to begin clinical trials in 2021, had already generated "significant interest".
"The potential of the preCISION platform to significantly improve outcomes for patients treated with existing cancer therapies through improved safety, tolerability and dosing regimens is enormous.
"In addition, Avacta is combining the preCISION technology with the 'Affimer' platform to create an entirely new class of proprietary TMAC drug conjugates."
At 0840 GMT, shares in Avacta Group were down 3.43% at 135.2p.
23 Apr 2024 14:26
UK earnings, trading statements calendar - next 7 days
| Wednesday 24 April | |
| 1Spatial PLC | Full Year Results |
| abrdn PLC | Trading Statement |
| Ecora Resources PLC | Trading Statement |
| Fresnillo PLC | Trading Statement |
| Lloyds Banking Group PLC | Q1 Results |
| Nichols PLC | Trading Statement |
| PensionBee Group PLC | First Quarter Results |
| PZ Cussons PLC | Trading Statement |
| Quilter PLC | Q1 Results |
| Reckitt Benckiser Group PLC | Trading Statement |
| Sanderson Design Group PLC | Full Year Results |
| Serica Energy PLC | Full Year Results |
| Star Energy Group PLC | Full Year Results |
| Tortilla Mexican Grill PLC | Full Year Results |
| Tracsis PLC | Half Year Results |
| Warpaint London PLC | Full Year Results |
| Thursday 25 April | |
| Aquila European Renewables PLC | Full Year Results |
| Argo Blockchain PLC | Full Year Results |
| AstraZeneca PLC | Q1 Results |
| Barclays PLC | Q1 Results |
| Checkit PLC | Full Year Results |
| Coca-Cola Europacific Partners PLC | Trading Statement |
| Destiny Pharma PLC | Full Year Results |
| Dillistone Group PLC | Full Year Results |
| Focusrite PLC | Half Year Results |
| Gem Diamonds Ltd | Trading Statement |
| Hikma Pharmaceuticals PLC | Trading Statement |
| Hummingbird Resources PLC | Trading Statement |
| Ibstock PLC | Trading Statement |
| Inchcape PLC | Trading Statement |
| J Sainsbury PLC | Full Year Results |
| London Stock Exchange Group PLC | Q1 Results |
| Persimmon PLC | Trading Statement |
| Pinewood Technologies Group PLC | Full Year Results |
| PPHE Hotel Group Ltd | Trading Statement |
| PureTech Health PLC | Full Year Results |
| Relx PLC | Trading Statement |
| Renewi PLC | Trading Statement |
| Schroders PLC | Q1 Results |
| Skillcast Group PLC | Full Year Results |
| Travis Perkins PLC | Trading Statement |
| Trifast PLC | Trading Statement |
| Unilever PLC | Q1 Results |
| WAG Payment Solutions PLC | Trading Statement |
| Weir Group PLC | Trading Statement |
| WH Smith PLC | Half Year Results |
| WPP PLC | Trading Statement |
| Zinc Media Group PLC | Full Year Results |
| Friday 26 April | |
| Facilities by ADF PLC | Full Year Results |
| Kingspan Group PLC | Trading Statement |
| NatWest Group PLC | Q1 Results |
| Pearson PLC | Trading Statement |
| Record PLC | Trading Statement |
| Smurfit Kappa Group PLC | Trading Statement |
| Taylor Maritime Investments Ltd | Trading Statement |
| Monday 29 April | |
| Beazley PLC | Trading Statement |
| Biome Technologies PLC | Full Year Results |
| Christie Group PLC | Full Year Results |
| Gresham Technologies PLC | Full Year Results |
| Jadestone Energy PLC | Full Year Results |
| Oxford BioMedica PLC | Full Year Results |
| SpaceandPeople PLC | Full Year Results |
| Tuesday 30 April | |
| Avacta Group PLC | Full Year Results |
| Card Factory PLC | Full Year Results |
| Capital & Regional PLC | Full Year Results |
| Coca-Cola HBC AG | Trading Statement |
| Elementis PLC | Trading Statement |
| essensys PLC | Half Year Results |
| Fadel Partners Inc | Full Year Results |
| Glencore PLC | Trading Statement |
| Hargreaves Lansdown PLC | Trading Statement |
| Howden Joinery PLC | Trading Statement |
| HSBC Holdings PLC | Q1 Results |
| Kelso Group PLC | Full Year Results |
| Northcoders Group PLC | Full Year Results |
| Phoenix Spree Deutschland Ltd | Full Year Results |
| RBG Holdings PLC | Full Year Results |
| Rotork PLC | Trading Statement |
| Safestore Holdings PLC | Half Year Results |
| Shield Therapeutics PLC | Full Year Results |
| St James's Place PLC | Trading Statement |
| Whitbread PLC | Full Year Results |
| Comments and questions to newsroom@alliancenews.com | |
| A full 21-day events calendar is provided each day with a subscription to Alliance News UK Professional. | |
| Copyright 2024 Alliance News Ltd. All Rights Reserved. | |